RLYB Rallybio Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLYB

Price (delayed)

$1.84

Market cap

$69.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.84

Enterprise value

$45.47M

Highlights
RLYB's debt is down by 29% year-on-year and by 8% since the previous quarter
The EPS is up by 12% year-on-year but it has declined by 3.4% since the previous quarter
The equity has declined by 37% year-on-year and by 14% since the previous quarter
The quick ratio has contracted by 25% YoY and by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of RLYB
Market
Shares outstanding
37.81M
Market cap
$69.57M
Enterprise value
$45.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$74.56M
EBITDA
-$74.41M
Free cash flow
-$60.28M
Per share
EPS
-$1.84
Free cash flow per share
-$1.49
Book value per share
$2.81
Revenue per share
$0
TBVPS
$2.86
Balance sheet
Total assets
$115.62M
Total liabilities
$9.44M
Debt
$392,000
Equity
$106.18M
Working capital
$105.53M
Liquidity
Debt to equity
0
Current ratio
12.39
Quick ratio
11.87
Net debt/EBITDA
0.32
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-53.4%
Return on equity
-56.9%
Return on invested capital
-72.5%
Return on capital employed
-70.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RLYB stock price

How has the Rallybio stock price performed over time
Intraday
0.55%
1 week
8.24%
1 month
10.18%
1 year
-65.93%
YTD
-23.01%
QTD
-0.54%

Financial performance

How have Rallybio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$78.93M
Net income
-$74.56M
Gross margin
N/A
Net margin
N/A
RLYB's operating income is down by 16% year-on-year and by 5% since the previous quarter
Rallybio's net income has decreased by 12% YoY and by 6% QoQ

Growth

What is Rallybio's growth rate over time

Valuation

What is Rallybio stock price valuation
P/E
N/A
P/B
0.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 12% year-on-year but it has declined by 3.4% since the previous quarter
RLYB's price to book (P/B) is 46% lower than its last 4 quarters average of 1.2
The equity has declined by 37% year-on-year and by 14% since the previous quarter

Efficiency

How efficient is Rallybio business performance
RLYB's return on equity is down by 31% year-on-year and by 19% since the previous quarter
Rallybio's return on assets has decreased by 30% YoY and by 18% QoQ
The ROIC has declined by 14% since the previous quarter

Dividends

What is RLYB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLYB.

Financial health

How did Rallybio financials performed over time
The total assets has declined by 36% year-on-year and by 13% since the previous quarter
The current ratio has declined by 26% year-on-year and by 12% since the previous quarter
RLYB's debt is 100% smaller than its equity
The equity has declined by 37% year-on-year and by 14% since the previous quarter
RLYB's debt is down by 29% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.